
|Videos|September 13, 2022
Gregory Warren Discusses Measuring Value and Scaling Up Value-Based Contracting
Author(s)Laura Joszt, MA, Peter Wehrwein
Thus far, value-based contracts for prescription drugs has not been transformative because of the scalability challenge for payers, explained Gregory Warren, FSA, FCA, MAAA, partner and consulting actuary with Axene Health Partners.
Advertisement
Thus far, value-based contracts for prescription drugs has not been transformative because of the scalability challenge for payers, explained Gregory Warren, FSA, FCA, MAAA, partner and consulting actuary with Axene Health Partners.
Warren was the keynote speaker on day 2 of the 2022 PBMI Annual National Conference in Orlando, Florida.
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FAQ: The uncertain future of enhanced ACA premium subsidies and what it means for U.S. healthcare
2
Shingles vaccine protects against shingles, slows biological aging
3
FDA approves combination therapy for blurry vision
4
Higher use, not higher prices, drove a 50% spike in urgent care spending
5



























